The Cordis Selution SLR drug-eluting balloon illustrated during a percutaneous coronary intervention. [Illustration courtesy ...
Medical Device Network on MSN
FDA approves Cordis SELUTION SLR for coronary in-stent restenosis
The device has obtained breakthrough device designation and is supported by results from the SELUTION4ISR trial.
Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus ...
The newly approved device from Cordis provides therapy over an extended period of time without leaving a permanent implant ...
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
The US Food and Drug Administration has approved the Selution SLR sirolimus-eluting balloon for the treatment of coronary ...
SELUTION DeNovo Trial - the largest randomized Drug Eluting Balloon trial - demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions.
Usually, Cordis is the company that is acquired in transactions that reach past the $1 billion threshold. However, the Hialeah, FL-based company is on the other side of the table – announcing it was ...
Over a beer, Shar Matin would have a lot of advice to give a peer about how to take a business like Cordis and essentially rebuild it as an independent company. Today, when the name Guidant comes up ...
The FDA approved a next-generation sirolimus-eluting balloon for the treatment of coronary in-stent restenosis, Cordis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results